Search
Displaying 561–570 of 611 for “retinal diseases”
-
Research News
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
-
FDA Approves Genentech’s Susvimo for Treating Wet AMD
Research NewsThe approach significantly reduces the need for regular ocular injections.
-
Telling His Story of Resilience
Beacon StoriesChad has been working in the corporate world for the last 20 years. But after becoming the first blind executive to graduate from the Harvard Business School leadership program, he realized his purpose in life is to help others by sharing the lessons he learned while losing his eyesight. He can now add published author to his repertoire with his new book, Blind Ambition.
-
Apellis to Seek FDA Approval of its Dry AMD Drug
Research NewsKnown as APL-2, the drug met its primary endpoint in the OAKS clinical trial but not the DERBY trial
-
Seeing Through Your Disability
Beacon Stories30-year-old Lance Johnson is a video editor and podcaster living in Brooklyn, New York. Despite being diagnosed with retinitis pigmentosa (RP) at a young age, Lance has never let his RP change his drive and passion for creating.
-
Biogen’s Phase 3 Clinical Trial for its Choroideremia Gene Therapy Doesn’t Meet Endpoints
Research NewsAdditional results from the trial will be reported at a future scientific meeting
-
ARVO 2021 Highlight: Update on Clinical Trial of jCyte’s Cellular Therapy for RP
Research NewsCellular treatment provided significant improvements in visual acuity for subpopulation of patients with better vision
-
Beacon Stories
American Banker dubbed her as “the sharpest mind analyzing banking policy today – maybe ever.”
-
Managing Your Mindset, Embracing Your Voice
WellnessCharity’s recent rapid decline in vision due to RP and her daughter’s diagnosis with RP has caused her to open up about her vision loss journey. After getting involved with the Foundation, Charity now feels like she has a voice to help others in the visually impaired community.
-
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Research NewsCompany will seek marketing approval for the emerging therapy
